LYVE1 and hepatocellular carcinoma: It is currently well established that along with HCC progression, LSECs shed their specific markers, including the lymphatic vessel endothelial hyaluronan receptor-1 (LYVE-1), CD32b, stabilin-1, and stabilin-2 [66,68].